Extended MORE data show no breast effect for raloxifene

With treatment up to 8 years, raloxifene has no impact on benign breast conditions, symptoms, or biopsies, according to extended data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. The findings were presented by investigators from Eli Lilly and Company at this year's NAMS meeting.

Previous MORE analyses had found similar outcomes in postmenopausal women treated with 60 mg per day of raloxifene. The new analysis looked at 7,705 postmenopausal women who had received 60 or 120 mg/d of raloxifene in MORE and continued to receive 60 mg/d for an additional 4 years in CORE (Continuing Outcomes Relevant to Evista). At each clinic visit, reports of benign breast conditions, breast symptoms, and breast biopsies were collected through nonspecific questioning.

No statistically significant differences were found for conditions including cyst, fibrocystic breast disease, and discharge between the women who received raloxifene and those on placebo for up to 8 years.